Tenosynovial Giant Cell Tumor Therapeutics Market Size, Share, and Industry Analysis, By Drug Type (VIMSELTINIB (ROMVIMZA), PEXIDARTINIB (TURALIO), and Others), By Type (Localized TGCT and Diffuse TGCT), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global tenosynovial giant cell tumor therapeutics market is witnessing significant growth due to the rise in the prevalence of tenosynovial giant cell tumor in the adult population. Additionally, the increase in research and development activities boosts the market growth. Tenosynovial giant cell tumor (TGCTs) refers to a group of rare diseases, and it is a non-cancerous but aggressive tumor leading to significant joint pain and dysfunction. The tenosynovial giant cell tumor develops in the synovium, bursae, and tendon sheaths of joints.

• For instance, according to the data published by Future Oncology Journal in February 2024, the annual prevalence of tenosynovial giant cell tumor in the USA in 2020 was approximately 16,250 cases. The rise in prevalence increases the adoption of tenosynovial giant cell tumor therapeutics products, which leads to market growth.

Tenosynovial Giant Cell Tumor Therapeutics Market Driver

Rise in Research and Development Activities Boosts Market Growth

The increasing research and development activities globally have significantly driven the growth of the tenosynovial giant cell tumor therapeutics market. Additionally, other factors, such as the rise in the prevalence of TGCTs, advancement in targeted therapies, and government support, also help to boost the market growth during the forecast period.

• For instance, in August 2024, the U.S. Food and Drug Administration accepted Deciphera’s New Drug Application (NDA) for Vimseltinib, used for the treatment of patients with tenosynovial giant cell tumor (TGCT). The rise in government support and targeted therapies increases the TGCTs product adoption and is expected to drive the market growth.

Tenosynovial Giant Cell Tumor Prevalence (Number of Cases), U.S., 2020

According to the data published in Future of Oncology in April 2024, the graph projects the number of cases of tenosynovial giant cell tumors. The Localized TGCT has a larger number of cases than the diffuse TGCT in the U.S.

Tenosynovial Giant Cell Tumor Therapeutics Market Restraint

Adverse Drug Reaction Can Limit Market Growth

The unfavourable side effects of the drugs may limit the growth of the market during the forecast period. Additionally, other factors, such as high-cost treatment, limited patient population, and limited treatment options, can also lower the market growth.

• For instance, in June 2020, Europe rejected the approval for PEXIDARTINIB (TURALIO), a drug used in the treatment of tenosynovial giant cell tumor. PEXIDARTINIB (TURALIO) is rejected due to its life-threatening hepatotoxic effects, leading to the unfavorable risk-benefit ratio in the treatment of the non-fatal condition of tenosynovial giant cell tumor. These types of side effects are expected to reduce product adoption, which leads to limiting the market growth.

Tenosynovial Giant Cell Tumor Therapeutics Market Opportunity

The Pipeline Candidates Boost the Market Growth in the Future

The rise in research and development focus and the development of new targeted therapies for the treatment of tenosynovial giant cell tumor (TGCT) are expected to boost market growth in the future. Additionally, ongoing clinical trials, government support, and high investment in R&D may support market growth in the near future.

• For instance, in April 2025, SynOx Therapeutics Limited, a biopharmaceutical company, received fast-track designation from the U.S. Food and Drug Administration for Emactuzumab, a drug used in the treatment of tenosynovial giant cell tumors (TGCT). These types of pipeline drugs may increase the adoption of tenosynovial giant cell tumor therapeutics products and are expected to drive market growth during the forecast period.

Key Insights

The report covers the following key insights:

• Prevalence of Tenosynovial Giant Cell Tumor, By Key Countries
• New Product Launches/ Approvals, By Key Players
• Pipeline Analysis, By Key Players
• Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• Impact of COVID-19 on the Market

Segmentation

Analysis by Drug Type

By drug type, the market is segmented into VIMSELTINIB (ROMVIMZA), PEXIDARTINIB (TURALIO), and others. The VIMSELTINIB (ROMVIMZA) segment is expected to grow significantly during the forecast period. The growth of the segment is augmented by its effectiveness and tolerability. As compared to the other approved drugs, VIMSELTINIB (ROMVIMZA) gives a better quality of life without harming the different body organs.

• For instance, according to the data published on Ono Pharmaceutical Co., Ltd in February 2025, the Phase 3 MOTION study for VIMSELTINIB (ROMVIMZA) shows that it has the ability to shrink tumors without any liver injury. These features help to improve the quality of a patient’s life and increase its adoption rate, leading to a boost in market growth.

Analysis by Type

Based on type, the market is segmented into localized TGCT and diffuse TGCT segments. The diffuse TGCT segment is expected to hold a significant portion of the market. The growth of the segment is attributed to the rise in incidence of diffuse TGCT. Diffuse TGCT has a high reoccurrence rate after surgery, and it has various treatment options, leading to a rise in the adoption rate for tenosynovial giant cell tumor and supporting market growth.

• For instance, according to the data published by the Life Raft Group in 2024, diffuse TGCT has a high reoccurrence rate after surgery, and PEXIDARTINIB (TURALIO) is used to treat it. The high reoccurrence rate is expected to raise the adoption rate of tenosynovial giant cell tumor products and lead to high market growth.

Analysis by Distribution Channel

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant share of the market in 2024. The substantial share in the segment is due to the tenosynovial giant cell tumor is a rare disease and requires planning and monitoring the treatment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the tenosynovial giant cell tumor therapeutics market in 2024. The region's growth is augmented by the increasing prevalence of tenosynovial giant cell tumor and the presence of advanced healthcare facilities for better treatment options. Moreover, the rise in demand for novel targeted therapies resulted in an increase in research and development activities also supports market growth.

• For instance, in September 2022, AmMax Bio, Inc., a biopharmaceutical company, developed innovative drugs in oncology, such as targeting the colony-stimulating factor 1 receptor (CSF1R). They received fast-track designation from the U.S. Food and Drug Administration for the AMB-05X drug used in the treatment of tenosynovial giant cell tumor (TCGT).

Europe holds significant shares of the market based on the rise in the prevalence of tenosynovial giant cell tumor and the increase in R&D activities for rare diseases. Additionally, the growth of the region is due to several established research institutions. The favorable government policies and developed research infrastructure, such as high-tech labs, also support the market growth.

• For instance, according to the data published by the European Medicines Agency in March 2023, a drug used in the treatment of tenosynovial giant cell tumor, localized and diffuse type given an orphan designation.

Asia Pacific is expected to grow substantially in the forthcoming years. This growth is attributed to the rise in the scope for research and development activities.

Key Players Covered

The global tenosynovial giant cell tumor therapeutics market is partially consolidated with a few key players. The report includes the profiles of the following key players:

• Daiichi Sankyo, Inc. (Japan)
• Deciphera Pharmaceuticals, LLC (U.S.)
• SynOx Therapeutics Limited (Ireland)
• Ono Pharmaceutical Co., Ltd. (Japan)
• Merck KGaA (Germany)
• AmMax Bio Inc. (U.S.)
• Elixiron Immunotherapeutics, Inc. (China)

Key Industry Developments

• In February 2025, Ono Pharmaceutical Co., Ltd. received the U.S. Food and Drug Administration approval for VIMSELTINIB (ROMVIMZA), a kinase inhibitor, used in the treatment of adult patients with tenosynovial giant cell tumor (TGCT).
• In April 2024, Deciphera Pharmaceuticals, LLC entered into a merger agreement with Ono Pharmaceutical Co., Ltd. for USD 2.4 billion. These strategic mergers and acquisition supports the market growth by innovating new products.